FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biochemistry. Described is antibody, which specifically binds with "receptor of advanced glycation endproducts" (RAGE). Claimed are: nucleic acid, which codes described antibody, composition for application as medication for treatment of disease or disorder, associated with RAGE. Also claimed is method of diagnosing RAGE-associated disease or disorder.
EFFECT: invention extends arsenal of means for treatment and diagnostics of RAGE-associated diseases.
12 cl, 5 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADVANCED GLYCATION END PRODUCT (RAGE) RECEPTOR ANTIBODIES AND USING THEM | 2009 |
|
RU2518351C2 |
| IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| ANTIBODIES AGAINST G-CSFR AND USE THEREOF | 2012 |
|
RU2605595C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| IMMUNOGLOBULIN WITH DOUBLE VARIABLE DOMAINS AND ITS APPLICATIONS | 2006 |
|
RU2515108C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
